Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma

Source: MDLinx, September 2020

Given that significantly longer relapse-free survival with 12 months of adjuvant dabrafenib plus trametinib vs placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations has been reported in the earlier reported primary analysis of this phase 3 trial, researchers undertook this investigation to corroborate the stability of the relapse-free survival benefit.

They present 5-year outcomes for relapse-free survival as well as survival without distant metastasis as the site of the first relapse. Participants were 870 patients with resected stage III melanoma with BRAF V600E or V600K mutations.

These were randomized to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.

READ THE ORIGINAL FULL ARTICLE